Oral contraceptive pill as treatment for primary dysmenorrhoea

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Wong, Chooi L ^a   Farquhar, Cindy ^b   Roberts, Helen ^c   Proctor, Michelle ^d  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c NATIONAL WOMEN S HOSPITAL   (New Zealand)

^d Psychological Service   (New Zealand)

Author keywords

Contraceptives, oral, combined *therapeutic use ; Dysmenorrhea *drug therapy ; Female; Humans; Randomized controlled trials as topic

Indexed keywords

CHLORMADINONE ACETATE; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; MESTRANOL; MESTRANOL PLUS NORETHISTERONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANALGESIA; CHI SQUARE TEST; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; EMBASE; HEADACHE; HUMAN; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN; FEMALE; RANDOMIZED CONTROLLED TRIAL;

CONTRACEPTIVES, ORAL, COMBINED; DYSMENORRHEA; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70349084627     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002120.pub2     Document Type: Review

References (41)

1. Bassol S, Alvarado A, Celis C, Cravioto MC, Peralta O, Montano R, et al.Latin American experience with two low-dose oral contraceptives containing 30μg ethinylestradiol/75μg gestodene and 20μg ethinyl estradiol/150μg desogestrel. Contraception 2000;62(3):131-135
2. Buttram VC, Kaufman RH. Primary dysmenorrhoea: combination vs sequential therapy. Texas Medicine 1969;65(8):52-55
3. Buttram VC, Kaufman RH. Primary dysmenorrhoea: combination vs sequential therapy. Texas Medicine 1969;65(8):52-55
4. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. Acta Psychiatrica Scandinavia Supplementum 1972;236:1-86.
5. Davis AR, Osborne LM, O'Connell KJ, Westhoff CL. Challenges of conducting a placebo-controlled trial for dynmenorrhea in adolescents. Journal of Adolescent Health 2006;39:607-609 [DOI: 10.101.16/j.jadohealth.2006.03.019]
6. * Davis AR, Westhoff C, O'Connell K, Callagher N. Oral contraceptives for dysmenorrhea in adolescent girls: A randomized trial. Obstetrics & Gynecology 2005;106(1):97-104.
7. O'Connell K, David AR, Kerns J. Oral contraceptives: side effects and depression in adolsecent girls. Contraception 2007;75:299-304. [: 10.1016/j.contraception.2006.09.008] (Pubitemid 46385916)
8. Endrikat J, Dusterberg B, Ruebig A, Gerlinger C, Strowitzki T. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 1999;60(5):269-274 (Pubitemid 30100602)
9. General Practitioner Research Group. Dysmenorrhoea unrelieved by an oral contraceptive. Practitioner 1968;200:856-859
10. Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002;66(6):393-399 (Pubitemid 37338053)
11. Nakano R, Takemura H. Treatment of function dysmenorrhoea: a double-blind study. Acta Obstetrica et Gynaecologica Japonica 1971;18(1):41-44
12. Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20μg ethinyl estradiol and either 150μg desogestrel and 75μg gestodene. The European Journal of Contraception and Reproductive Health Care 1998;3(4):179-189 (Pubitemid 128690545)
13. Winkler UH, Ferguson H, Mulders JAPA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20μg ethinylestradiol. Contraception 2004;69(6):469-476 (Pubitemid 38638747)
14. Creatsas G, Cardamakis E, Deligeoroglou E, Hassan E, Tzingounis V. Tenoxicam versus lynestrenol-ethinyl estradiol treatment of dysfunctional uterine bleeding cases during adolescence. Journal of Paediatric & Adolescent Gynaecology 1998;11(4):177-180. (Pubitemid 28528903)
15. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. The European Journal of Contraception and Reproductive Health Care 2000;5(2):124-134 (Pubitemid 30470064)
16. Iannotti G, DeFalco F, Paladini D, Ferraro F, Ragone R, Facchiano C, Ferrara A. Estrogen-progestagen and prostaglandin inhibitors in the treatment of primary dysmenorrhoea [Estroprogestinici ed antiprostaglandinici nelle terapia della dismenorrea primaria]. Giornale Italiano di Ostetricia e Ginecologia 1991;13(2):87-90.
17. Karasawa Y. Treatment of dysmenorrhoea with a mixed preparation of norethindrone and mestranol (S-3800C). Sanfujinka No Jissai - Practice of Gynecology & Obstetrics 1968;17(10):913-918
18. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (Desogestrel/Ethinyl Estradiol) and Ortho-Novum 7/7/7(Norethindrone/Ethinyl Estradiol): A randomised clinical trial. Contraception 2000;61(5):295-302.
19. Kremser E, Mitchell GM. Treatment of primary dysmenorrhoea with a combined type oral contraceptive - a double blind study. Journal of the American College Health Association 1971;19(3):195-196
20. Kristjansdottir J, Johansson EDB, Ruusuvaara L. The cost of the menstrual cycle in young Swedish women. The European Journal of Contraception and Reproductive Health Care 2000;5(2):152-156 (Pubitemid 30470068)
21. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomised trial. Contraception 2003;67(1):9-13. (Pubitemid 36084281)
22. LaGuardia KD, Shangold G, Fisher A, Friedman A, Kafrissen M, the Norgestimate Study Group. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradio. Contraception 2003;67(6):431-437. 2003;67(6):431-437 (Pubitemid 36695107)
23. Matthews AE, Clarke JE. Double-blind trial of a sequential oral contraceptive (Sequens) in the treatment of dysmenorrhoea.. Journal of Obstetrics & Gynaecology of the British Commonwealth 1968;75(11):1117-1122
24. Moore C, Feichtinger W, Klinger G, Melliger U, Spona J, Walter F, Winkler UH, Zahradnik HP. Clinical findings with the dienogest-containing oral contraceptive Valette(TM). Drugs of Today 1999;35(Suppl. C):53-68. (Pubitemid 29342747)
25. Reisman H, Deborah M, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100μg levonorgestrel with 20μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. American Journal of Obstetrics & Gynecology 1999;181(5 part 2):S45-S52.
26. Tallian F. Therapeutic possiblities using newer types of combined pills [Terapias lehetosegek ujabb tipusu kombinalt hormontablettakkal]. Magyar Noorvosok Lapja 1994;57:189-192
27. Brill K, Norpoth T, Schnitker J, Albring M. Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users. Contraception 1991;43(2):101-110.
28. Chan WY, Dawood MY, Fuchs F. Prostaglandins in primary dysmenorrhea: Comparison of prophlactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. American Journal of Medicine 1981;70:535-541 (Pubitemid 11153958)
29. Coco AS. Primary Dysmenorrhoea. American Family Physician 1999;60(2):489-496
30. Dawood MY. Ibuprofen and dysmenorrhea. American Journal of Medicine 1984;77(1A):87-94.
31. Dawood MY. Dysmenorrhea. Clinical Obstetrics and Gynecology 1990;33(1):168-178
32. Dawood MY. Primary Dysmenorrhea - Advances in pathogenesis and management. Obstetrics Gynaecology 2006;108:428-441
33. Gauthier A, Upmalis D, Dain M. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol. Acta Obstetricia et Gynecologica Scandinavica Supplement 1992;71(Suppl 156):27-32.
34. Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertility and Sterility 1971;22(9):609-623
35. Goldzieher JW, Zamah NM. Oral contraceptive side effects: Where's the beef?. Contraception 1995;52:327-335
36. Karnaky KJ. Development of the oral contraceptives. American Journal of Obstetrics and Gynecology 1975;123(7):771-772.
37. Melzack R, Katz J. Pain measurement in persons in pain. In: PD Wall, R Melzack editor(s). Textbook of Pain. 3rd Edition. London: Churchill Livingstone, 1994:337-351.
38. Milsom I, Andersch B. Effect of various oral contraceptive combinations on dysmenorrhea. Gynaecologic and Obstetric Investigation 1984;17:284-292. (Pubitemid 14103946)
39. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 1990;42(5):497-506.
40. Smith RP. Cyclic pain and dysmenorrhea. Obstetrics and Gynecology Clinics of North America 1993;20(4):752-764.
41. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858]